SCHEMBL29732610

CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	KISS1R	Q969F8	6/20	0.54

▸	MAGI3	Q5TCQ9	1/20	0.53

▸	IL23R	Q5VWK5	5/20	0.50

▸	NPY1R	P25929	3/20	0.50

▸	NPY2R	P49146	3/20	0.50

▸	NPY4R	P50391	3/20	0.50

▸	PRMT1	Q99873	1/20	0.48

▸	SIRT5	Q9NXA8	1/20	0.48

▸	GHSR	Q92847	1/20	0.48

▸	CTSB	P07858	1/20	0.48

▸	CTSK	P43235	1/20	0.48

▸	ACE	P12821	1/20	0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30339696	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL30148460	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL30302874	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL29800092	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL30305295	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL31110538	1.00	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL30093131	0.98	MAGI3 (0.52)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL30945346	0.98	MAGI3 (0.52)	KISS1RMAGI3IL23RNPY1RNPY2R
SCHEMBL29732783	0.97	MAGI3 (0.54)	KISS1RMAGI3IL23RPRMT1
SCHEMBL30305302	0.97	KISS1R (0.54)	KISS1RMAGI3IL23RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250195611-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	PEPTILOGICS, INC.	2025-06-19	—	—	US	claimed
US-20240252586-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	PEPTILOGICS, INC.	2024-08-01	—	—	US	claimed
CN-118265536-A	Engineered antibacterial peptides and uses thereof	肽逻辑公司	2024-06-28	—	—	CN	claimed
US-20230106943-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	PEPTILOGICS, INC.	2023-04-06	—	—	US	claimed
US-20220249599-A1	TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES	PEPTILOGICS, INC.	2022-08-11	—	—	US	claimed
US-20250320266-A1	Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US)	2025-10-16	—	—	US	disclosed
US-20250277002-A1	ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE	PEPTILOGICS, INC.	2025-09-04	—	—	US	disclosed
US-20250195611-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	PEPTILOGICS, INC.	2025-06-19	—	—	US	disclosed
US-20240252586-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	PEPTILOGICS, INC.	2024-08-01	—	—	US	disclosed
CN-118265536-A	Engineered antibacterial peptides and uses thereof	肽逻辑公司	2024-06-28	—	—	CN	disclosed
US-20240115654-A1	INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES	PEPTILOGICS, INC.	2024-04-11	—	—	US	disclosed
US-20230107222-A1	ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE	PEPTILOGICS, INC.	2023-04-06	—	—	US	disclosed
US-20220249599-A1	TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES	PEPTILOGICS, INC.	2022-08-11	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250195611-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	VIP, SPPL2B, HM13	KISS1R 3745/4885MAGI3 2045/4885IL23R 610/4885
US-20220249599-A1	TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES	NGLY1, ANPEP, VIP	KISS1R 1422/4885MAGI3 3222/4885IL23R 1023/4885
US-20240115654-A1	INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES	IAPP, VIP, NGLY1	KISS1R 3225/4885MAGI3 4082/4885IL23R 1571/4885
US-20230106943-A1	ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF	VIP, SPPL2B, HM13	KISS1R 3745/4885MAGI3 2045/4885IL23R 610/4885
US-20250277002-A1	ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE	NGLY1, PRF1, LNPEP	KISS1R 3536/4885MAGI3 3116/4885IL23R 2492/4885
US-20230107222-A1	ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE	NGLY1, PRF1, LNPEP	KISS1R 3536/4885MAGI3 3116/4885IL23R 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.